Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors :: Watanabe R
Tomita N
Kishimoto K
Koyama S
Ogusa E
Ishii Y
Miyashita K
Matsuura S
Fujisawa S
Hattori Y
Takasaki H
Fujita A
Ohshima R
Kuwabara H
Hashimoto C
Fujimaki K
Sakai R
Ishigatsubo Y
Source :: Leukemia research [Leuk Res] 2013 Oct; Vol. 37 (10), pp. 1208-12. Date of Electronic Publication: 2013 Aug 05.
Publication Year :: 2013
Abstract: Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.<br /> (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Full Text Access

Tools